Chisato Narita, Fumihiko Urabe, Wataru Fukuokaya, Kosuke Iwatani, Yu Imai, Keiji Yasue, Keiichiro Mori, Koichi Aikawa, Takafumi Yanagisawa, Shoji Kimura, Kojiro Tashiro, Shunsuke Tsuzuki, Yuta Yamada, Steffi Kar Kei Yuen, Jeremy Yuen-Chun Teoh, Tatsuya Shimomura, Hiroki Yamada, Akira Furuta, Jun Miki, Takahiro Kimura
BACKGROUND: The CheckMate274 trial has reported enhanced disease-free survival rates in patients with stage pT3-4/ypT2-4 or pN+ urothelial carcinoma (UC) undergoing adjuvant nivolumab therapy. This study compares prognostic differences between urothelial carcinoma of the bladder (UCB) and upper tract urothelial carcinoma (UTUC). METHODS: We retrospectively analyzed data from 719 patients with UC who underwent radical surgery, stratifying to patients at stage pT3-4 and/or pN+ without neoadjuvant chemotherapy (NAC) or at ypT2-4 and/or ypN+ with NAC (potential candidates for adjuvant immunotherapy), and to those who were not candidates for adjuvant immunotherapy...
March 21, 2024: Clinical Genitourinary Cancer